Navigation Links
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Date:4/14/2008

Restored sensitivity to cisplatin observed in ovarian carcinoma xenografts

DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that S-110, its DNA methyltransferase inhibitor, improves in vivo efficacy of decitabine (Abstract No. 2613).

Entitled, "Decitabine administered as a Dinucleotide prodrug increases its in vivo efficacy due to enhanced drug delivery and stability," the poster highlights data indicating that S-110 showed robust anti-tumor activity in prostate and cisplatin-resistant ovarian carcinoma xenograft models. Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancer model. Importantly, reduced toxicity was observed along with an increased half-life compared to decitabine.

"S-110's increased half-life, reduced toxicity and improvement of efficacy when compared to decitabine in its currently marketed formulations make it an attractive, next-generation hypomethylator for the treatment of hematoligic malignancies," said Dr. James Manuso, SuperGen's President and CEO. "As we develop S-110 further, we will continue to explore its potential to enhance solid tumors' sensitivity to standard chemotherapy agents, including cisplatin. We look forward to advancing this promising candidate to clinical trials later this year or early next year."

Copies of the 2008 AACR Annual Meeting poster presentations will be available in the pipeline section of SuperGen's Web site http://www.supergen.com.

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen Inc. SuperGen Inc.

SVP, Corporate Communications & Business Manager, Investor

Development Relations

Tel: (925) 560-0100 Tel: (925) 560-2845

E-mail: tenns@supergen.com E-mail:

mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
6. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
11. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... February 23, 2017 Obese people ... caseload for varicose veins in their body. The rising ... prompting the adoption of endovenous laser therapy for treatment ... endovenous laser therapy market, published by Future Market ... choices and consequences of obesity have collectively factored the ...
(Date:2/23/2017)... February 23, 2017 The fast-growing cannabis ... the United States . According to the 2017 Legal ... is expected to create 283,422 jobs by 2020, with an ... the next four years. The accelerating pace of cannabis legalization ... of legal cannabis market, which will further create more business ...
(Date:2/23/2017)... February 23, 2017 The top ... are GE Healthcare, Koninklijke Philips N.V., and Schiller. Collectively, ... the global market in 2015. Strong product portfolio and ... assessed to be aiding these players remain leaders in ... the players in the global market are likely to ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of ... “Imagine Me Beyond What You See” body image mannequin art competition. Selected from 15 ... showcased and the winner revealed at the 31st annual iaedp Symposium, March 22 – ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over Heels’ ... February 12th. Ms. Esparza qualified into this prestigious status after winning the ... Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards ... of the 2016 National Education Policy Center Bunkum Award. We invite you to enjoy ... , This year’s Bunkum winner is the Center for American Progress (CAP), for its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon ... TV’s “Mama June: From Not to Hot,” which will begin airing on February 24, ... known to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
Breaking Medicine News(10 mins):